LAVA Therapeutics (NASDAQ:LVTX) Short Interest Down 28.4% in March

LAVA Therapeutics (NASDAQ:LVTX) saw a large drop in short interest in March. As of March 31st, there was short interest totalling 137,100 shares, a drop of 28.4% from the March 15th total of 191,500 shares. Based on an average trading volume of 400,300 shares, the days-to-cover ratio is currently 0.3 days. Approximately 1.1% of the shares of the company are short sold.

Hedge Funds Weigh In On LAVA Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Virtu Financial LLC acquired a new stake in shares of LAVA Therapeutics in the 3rd quarter worth about $32,000. BNP Paribas Financial Markets bought a new position in LAVA Therapeutics in the 4th quarter worth about $40,000. Finally, Sanofi acquired a new stake in shares of LAVA Therapeutics in the fourth quarter valued at approximately $1,825,000.

LAVA Therapeutics Stock Up 6.5 %

Shares of LVTX stock opened at $1.31 on Friday. The business has a 50 day moving average of $1.20 and a two-hundred day moving average of $1.32. The company has a market cap of $34.46 million, a P/E ratio of -1.27 and a beta of 0.46. LAVA Therapeutics has a 52 week low of $0.85 and a 52 week high of $3.20.

LAVA Therapeutics (NASDAQ:LVTX) last released its quarterly earnings data on Friday, March 28th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.18. The company had revenue of $2.50 million for the quarter, compared to analyst estimates of $2.40 million. Analysts expect that LAVA Therapeutics will post -1.13 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “neutral” rating and set a $1.50 price objective on shares of LAVA Therapeutics in a research note on Monday, March 31st. Five research analysts have rated the stock with a hold rating, According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $3.17.

About LAVA Therapeutics

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.